Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) | Starlite/ChEMBL | References |
Homo sapiens | integrin, beta 7 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Loa Loa (eye worm) | integrin beta-2 | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Schistosoma japonicum | ko:K06464 integrin beta 2, putative | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Schistosoma japonicum | Integrin beta-3 precursor, putative | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Schistosoma mansoni | integrin beta subunit | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Schistosoma japonicum | Integrin beta-PS precursor, putative | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Echinococcus granulosus | integrin beta 2 | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Echinococcus multilocularis | integrin beta 2 | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Brugia malayi | Integrin beta pat-3 precursor | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | kinesin family 1 | 0.5209 | 1 | 1 |
Toxoplasma gondii | kinesin motor domain-containing protein | 0.0677 | 0.0396 | 0.5 |
Plasmodium falciparum | kinesin-5 | 0.0677 | 0.0396 | 0.5 |
Brugia malayi | Integrin beta pat-3 precursor | 0.0714 | 0.0476 | 1 |
Loa Loa (eye worm) | integrin beta-2 | 0.0714 | 0.0476 | 1 |
Schistosoma mansoni | kinesin eg-5 | 0.0677 | 0.0396 | 0.0462 |
Entamoeba histolytica | kinesin, putative | 0.0677 | 0.0396 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.4533 | 0.8566 | 1 |
Giardia lamblia | Kinesin-5 | 0.0677 | 0.0396 | 0.5 |
Plasmodium vivax | kinesin-5 | 0.0677 | 0.0396 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.26 nM | Alpha4-beta1 integrin binding affinity was assessed by measuring the reduction in binding of [125I]-VCAM-Ig to a suspension of Jurkat cells (a human T cell line alpha4-beta1-beta7) | ChEMBL. | 11755344 |
IC50 (binding) | = 0.26 nM | Alpha4-beta1 integrin binding affinity was assessed by measuring the reduction in binding of [125I]-VCAM-Ig to a suspension of Jurkat cells (a human T cell line alpha4-beta1-beta7) | ChEMBL. | 11755344 |
IC50 (binding) | = 13 nM | Alpha4-beta7 integrin binding affinity was determined in duplicate by a radioligand binding assay using [125I]-VCAM-Ig and a suspension of RPMI-8866 cells (a human B cell line alpha4-beta1-beta7+) | ChEMBL. | 11755344 |
IC50 (binding) | = 13 nM | Alpha4-beta7 integrin binding affinity was determined in duplicate by a radioligand binding assay using [125I]-VCAM-Ig and a suspension of RPMI-8866 cells (a human B cell line alpha4-beta1-beta7+) | ChEMBL. | 11755344 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.